Emerging Infectious Diseases — Learning from the Past and Looking to the Future

Author(s):  
Christopher Elias ◽  
John N. Nkengasong ◽  
Firdausi Qadri
Author(s):  
Toni Wandra

World Health Organization (WHO) defines zoonotic diseases (zoonoses) as those diseases and infections which are naturally transmitted between vertebrate animals and humans. More than 250 zoonoses have been described, over 60% of pathogens that cause diseases in humans are zoonoses of animals, and 75% of emerging infectious diseases. Most pandemics are caused by zoonoses.


2004 ◽  
Vol 359 (1447) ◽  
pp. 1049-1058 ◽  
Author(s):  
A. J. McMichael

During the processes of human population dispersal around the world over the past 50 000–100 000 years, along with associated cultural evolution and inter–population contact and conflict, there have been several major transitions in the relationships of Homo sapiens with the natural world, animate and inanimate. Each of these transitions has resulted in the emergence of new or unfamiliar infectious diseases. The three great historical transitions since the initial advent of agriculture and livestock herding, from ca . 10 000 years ago, occurred when: (i) early agrarian–based settlements enabled sylvatic enzootic microbes to make contact with Homo sapiens ; (ii) early Eurasian civilizations (such as the Greek and Roman empires, China and south Asia) came into military and commercial contact, ca . 3000–2000 years ago, swapping their dominant infections; and (iii) European expansionism, over the past five centuries, caused the transoceanic spread of often lethal infectious diseases. This latter transition is best known in relation to the conquest of the Americas by Spanish conquistadores , when the inadvertent spread of measles, smallpox and influenza devastated the Amerindian populations. Today, we are living through the fourth of these great transitional periods. The contemporary spread and increased lability of various infectious diseases, new and old, reflect the combined and increasingly widespread impacts of demographic, environmental, behavioural, technological and other rapid changes in human ecology. Modern clinical medicine has, via blood transfusion, organ transplantation, and the use of hypodermic syringes, created new opportunities for microbes. These have contributed to the rising iatrogenic problems of hepatitis C, HIV/AIDS and several other viral infections. Meanwhile, the injudicious use of antibiotics has been a rare instance of human action actually increasing ‘biodiversity’. Another aspect of this fourth transition is that modern hyper–hygienic living restricts microbial exposure in early life. This, in the 1950s, may have contributed to an epidemic of more serious, disabling, poliomyelitis, affecting older children than those affected in earlier, more endemic decades. As with previous human–microbe transitions, a new equilibrial state may lie ahead. However, it certainly will not entail a world free of infectious diseases. Any mature, sustainable, human ecology must come to terms with both the need for, and the needs of, the microbial species that help to make up the interdependent system of life on Earth. Humans and microbes are not ‘at war’; rather, both parties are engaged in amoral, self–interested, coevolutionary struggle. We need to understand better, and therefore anticipate, the dynamics of that process.


2017 ◽  
Vol 44 ◽  
pp. 28-30 ◽  
Author(s):  
Philippe Charlier ◽  
Jean-Michel Claverie ◽  
Philippe Sansonetti ◽  
Yves Coppens ◽  
Anaïs Augias ◽  
...  

GigaScience ◽  
2020 ◽  
Vol 9 (8) ◽  
Author(s):  
Dima Kagan ◽  
Jacob Moran-Gilad ◽  
Michael Fire

Abstract Background COVID-19 is the most rapidly expanding coronavirus outbreak in the past 2 decades. To provide a swift response to a novel outbreak, prior knowledge from similar outbreaks is essential. Results Here, we study the volume of research conducted on previous coronavirus outbreaks, specifically SARS and MERS, relative to other infectious diseases by analyzing >35 million articles from the past 20 years. Our results demonstrate that previous coronavirus outbreaks have been understudied compared with other viruses. We also show that the research volume of emerging infectious diseases is very high after an outbreak and decreases drastically upon the containment of the disease. This can yield inadequate research and limited investment in gaining a full understanding of novel coronavirus management and prevention. Conclusions Independent of the outcome of the current COVID-19 outbreak, we believe that measures should be taken to encourage sustained research in the field.


2020 ◽  
Vol 21 (11) ◽  
pp. 3843 ◽  
Author(s):  
Xinling Wang ◽  
Shuai Xia ◽  
Qian Wang ◽  
Wei Xu ◽  
Weihua Li ◽  
...  

In the past 17 years, three novel coronaviruses have caused severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the coronavirus disease 2019 (COVID-19). As emerging infectious diseases, they were characterized by their novel pathogens and transmissibility without available clinical drugs or vaccines. This is especially true for the newly identified COVID-19 caused by SARS coronavirus 2 (SARS-CoV-2) for which, to date, no specific antiviral drugs or vaccines have been approved. Similar to SARS and MERS, the lag time in the development of therapeutics is likely to take months to years. These facts call for the development of broad-spectrum anti-coronavirus drugs targeting a conserved target site. This review will systematically describe potential broad-spectrum coronavirus fusion inhibitors, including antibodies, protease inhibitors, and peptide fusion inhibitors, along with a discussion of their advantages and disadvantages.


Author(s):  
Ronghua Ding ◽  
Jinzhao Long ◽  
Mingzhu Yuan ◽  
Yuefei Jin ◽  
Haiyan Yang ◽  
...  

The continued global pandemic of coronavirus disease 2019 (COVID-19) poses a serious threat to global public health and social stability and it has become a serious global public health problem. Unfortunately, existing diagnostic and therapeutic approaches for the prevention and control of COVID-19 have many shortcomings. In recent years, the emerging CRISPR/Cas technology can complement the problems of traditional methods. Biological tools based on CRISPR/Cas systems have been widely used in biomedicine. In particular, they are advantageous in pathogen detection, clinical antiviral therapy, drug, and vaccine development. Therefore, CRISPR/Cas technology may have great potential for application in the prevention and control of COVID-19 and emerging infectious diseases in the future. This article summarizes the existing applications of CRISPR/Cas technology in infectious diseases with the aim of providing effective strategies for the prevention and control of COVID-19 and other emerging infectious diseases in the future.


Sign in / Sign up

Export Citation Format

Share Document